Thrombolytic therapy in acute MI

References

• Wasserman AG, Ross AM. Coronary thrombolysis. Curr Probl Cardiol 1989: 14(1): 1–54
   PubMedGoogle Scholar
• Herrick JB. Clinical features of sudden obstruction of the coronary arteries. JAMA 1912: 59(23): 2015–20
   Google Scholar
• Roberts WC, Buja LM. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction: a study of 107 necropsy patients. Am J Med 1972: 52(4): 425–43
   PubMed Web of Science ®Google Scholar
• DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980: 303(16): 897–902
   PubMed Web of Science ®Google Scholar
• Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986: 1(8478): 397–402
   PubMed Web of Science ®Google Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988: 2(8607): 349–60'
   PubMed Web of Science ®Google Scholar
• AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988: 1(8585): 545–9
   PubMed Web of Science ®Google Scholar
• Anderson JL, Rothbard RL, Hackworthy RA, et al. Multicenter reperfiision trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. J Am Coll Cardiol 1988: 11 (6): 1153–63
   PubMed Web of Science ®Google Scholar
• Collen D, Lijnen HR, Todd PA, et al. Tissue-type plasminogen activator: a review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 1989: 38(3): 346–88
   PubMed Web of Science ®Google Scholar
• The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989: 320(10): 618–27
   PubMed Web of Science ®Google Scholar
• Neuhaus KL, Feuerer W, Jeep-Tebbe S, et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989: 14(6): 1566–9
   PubMed Web of Science ®Google Scholar
• TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med 1985: 312(14): 932–6
   PubMed Web of Science ®Google Scholar
• Verstraete M, Bory M, Collen D, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985: 1(8433): 842–7
   PubMed Web of Science ®Google Scholar
• Cairns JA, Collins R, Fuster V, et al. Coronary thrombolysis. Chest 1989: 95(2 Suppl): 73–87S
   Web of Science ®Google Scholar
• Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990: 336(8707): 65–71
   PubMed Web of Science ®Google Scholar
• National Heart Foundation of Australia Coronary Thrombolysis Group. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet 1988: 1(8579): 203–8
   PubMed Web of Science ®Google Scholar
• Guerci AD, Gerstenblith G, Brinker JA, et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987: 317(26): 1613–8
   PubMed Web of Science ®Google Scholar
• O'Rourke M, Baron D, Keogh A, et al. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 1988: 77(6): 1311–5
   PubMed Web of Science ®Google Scholar
• White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987: 317(14): 850–5
   PubMed Web of Science ®Google Scholar
• The I.S.A.M. Stuck' Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986: 314(23): 1465–71
   PubMed Web of Science ®Google Scholar
• Bassand JP, Machecourt J, Cassagnes J, et al. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function. J Am Coll Cardiol 1989: 13(5): 988–97
   PubMed Web of Science ®Google Scholar
• Wilcox RG, Olsson CG, Skene AM, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988: 2(8610): 525–30
   PubMed Web of Science ®Google Scholar
• Berger PB, Ryan TJ. Inferior myocardial infarction: high-risk subgroups. Circulation 1990: 81(2): 401–11
   PubMed Web of Science ®Google Scholar
• Thrombolysis in the management of myocardial infarction. Proceedings of a symposium held in conjunction with the 38th annual scientific session of the American College of Cardiology. Anaheim, California, March 18, 1989. Hosp Pract (Off) 1989: 24(Suppl 1): 1–32
   PubMedGoogle Scholar
• Ross AM, Hoia J, Hamilton W et al. Heparin versus aspirin after recombinant tissue plasminogen activator therapy in myocardial infarction: a randomized trial. (Abstr) J Am Coll Cardiol 1990: 15(Suppl A): 64A
   PubMed Web of Science ®Google Scholar
• Collen D. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? Ann Intern Med 1990: 112(7): 529–38
   PubMed Web of Science ®Google Scholar
• Gertz SD, Kalan JM, Kragel AH, et al. Cardiac morphologic findings in patients with acute myocardial infarction treated with recombinant tissue plasminogen activator. Am J Cardiol 1990: 65(15): 953–61
   PubMed Web of Science ®Google Scholar
• Bossaert LL, Demey HE, Colemont LJ, et al. Prehospital thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Crit Care Med 1988: 16(9): 823–30
   PubMed Web of Science ®Google Scholar